Cite
HARVARD Citation
Sangha, R. et al. (2017). Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. Journal of drug assessment. pp. 10-17. [Online].